Lineage Cell Therapeutics Inc Share Price

NYSE: LCTX

Small Cap

$1.54

+0.16

(+11.15%)

Live

as on September 18, 2025 at 10:41 pm IST

$₹

Lineage Cell Therapeutics Inc Stock Performance

as on September 18, 2025 at 10:41 pm IST

Day's Low
Day's High
$1.4
Day's Price Range
$1.55
$1.54
9.09%
Downside
0.65%
Upside
52 Week's Low
52 Week's High
$0.37
52-Week Price Range
$1.42
$1.54
76.29%
Downside
-7.79%
Upside

Lineage Cell Therapeutics Inc share price movements today

Previous Close: $1.39
Open: $1.43
Volume: 2.0M
Day's Low - High: $1.4 - $1.55
52 Week Low - High: $0.37 - $1.42

Lineage Cell Therapeutics Inc Historical Returns

1 Month Return: + 8.59 %
3 Month Return: + 51.9 %
1 Year Return: + 57.95 %
3 Year Return: + 7.75 %
5 Year Return: + 41.84 %

Lineage Cell Therapeutics Inc Stock Fundamentals & Key Indicators

Check Lineage Cell Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$317.4M

EPS (TTM)

-0.1917

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-6.85

Industry PE ratio

0

P/B Ratio

0

PEG Ratio

0

EBITDA

-19.8M

Revenue (TTM)

10.9M

Profit Margin

0.00%

Return On Equity TTM

5148600.00%

Lineage Cell Therapeutics Inc Stock Valuation

Track how Lineage Cell Therapeutics Inc P/E has moved over time to understand its valuation trends.

Lineage Cell Therapeutics Inc in the last 5 years

Overview
Trends

Lowest (0.00x)

September 18, 2025

Industry (0.00x)

September 18, 2025

Today (-6.85x)

September 18, 2025

Highest (0.00x)

September 18, 2025

LowHigh

Today’s Price to Earnings Ratio: -6.85x

Lineage Cell Therapeutics Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Lineage Cell Therapeutics Inc with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Lineage Cell Therapeutics Inc	BUY	$317.4M	41.84%	-6.85	0.00%
Alnylam Pharmaceuticals, Inc.	BUY	$60.5B	241.54%	-505.15	-12.96%
Beone Medicines Ltd	NA	$38.7B	NA	NA	-3.89%
Vertex Pharmaceuticals Incorporated	BUY	$99.3B	45.88%	27.56	31.86%
Regeneron Pharmaceuticals, Inc.	BUY	$60.9B	5.45%	14.49	31.37%

Stock Returns calculator for Lineage Cell Therapeutics Inc Stock including INR - Dollar returns

The Lineage Cell Therapeutics Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

1Y
3Y
5Y

Lineage Cell Therapeutics Inc investment value today

Current value as on today

₹1,79,953

Returns

₹79,953

(+79.95%)

Returns from Lineage Cell Therapeutics Inc Stock

₹75,000 (+75%)

Dollar Returns*

₹4,953 (+4.95%)

Analyst Recommendation on Lineage Cell Therapeutics Inc Stock

Based on 12 analysts

BUY

83.33%

Buy

16.67%

Hold

0.00%

Sell

Based on 12 analysts, 83.33% of analysts recommend a 'BUY' rating for Lineage Cell Therapeutics Inc. Average target price of $4.17

Lineage Cell Therapeutics Inc Share Price Target

Get share price movements and forecasts by analysts on Lineage Cell Therapeutics Inc.

What analysts predicted

63.07%UPSIDE

Target Price

$4.17

Current Price

$1.54

Analyzed by

12 Analysts

Target

$4.17

Lineage Cell Therapeutics Inc target price $4.17, a slight upside of 63.07% compared to current price of $1.54. According to 12 analysts rating.

Lineage Cell Therapeutics Inc Stock's Interest Amongst Investors

Search interest for Lineage Cell Therapeutics Inc Stock has decreased by -17% in the last 30 days, reflecting a downward trend in search activity.

Time period: August 19, 2025 to September 18, 2025

Change:-17% versus previous 30 day period

Lineage Cell Therapeutics Inc Quarterly Profit & Loss

All numbers in Millions USD

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Total Revenue	2	3	1	2	1	1	3	2	1	2
Gross Profit	2	3	1	1	1	1	3	2	1	2
Operating Income	-6	-5	-6	-6	-6	-5	-3	-5	-6	-19
EBITDA	-6	-4	-6	-6	-6	-5	-3	-4	-6	-4
Interest Expense	0	0	-	0	-	-	-	-	-	-
Depreciation	0	0	0	0	0	0	0	0	0	0
Income Before Tax	-6	-5	-7	-4	-6	-5	-3	-3	-4	-30
Income Tax Expense	-1	0	0	0	0	0	0	0	-	-
Net Income	-4	-5	-7	-4	-6	-5	-3	-3	-4	-30
Net Profit Margin	-184.58%	-162.14%	-570.63%	-228.69%	-453.05%	-409.09%	-80.29%	-114.12%	-275.57%	-1101.77%

Lineage Cell Therapeutics Inc Annual Profit & Loss

All numbers in Millions USD

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Revenue	2	2	1	1	1	0	3	14	8	9
Gross Profit	1	1	1	1	1	0	2	13	8	9
Operating Income	-65	-58	-38	-41	-38	-26	-49	-22	-24	-21
EBITDA	-59	-54	-37	-37	-38	-24	-48	-21	-24	-20
Interest Expense	0	0	0	10	1	5	0	5	-	-
Depreciation	-	-	3	3	3	2	0	0	0	0
Income Before Tax	-62	18	-23	-47	-19	-21	-43	-25	-23	-18
Income Tax Expense	-4	-175	-37	0	-7	-1	-4	0	-1	0
Net Income	-46	33	-19	-45	-11	-20	-43	-26	-21	-18
Net Profit Margin	-1854.42%	1490.76%	-1114.73%	-3247.88%	-800.20%	-2675.94%	-1104.18%	-179.24%	-240.20%	-195.90%

Lineage Cell Therapeutics Inc Quarterly Cash Flow

All numbers in Millions USD

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Net Income	-5	-7	-4	-6	-5	-3	-3	-4	-30
Operating Cash Flow	-6	-5	-6	-5	-5	-5	-6	-4	-5
Investing Cash Flow	19	2	9	0	-8	3	2	1	0
Financing Cash Flow	5	0	0	14	0	0	21	5	0
Change in Cash	18	-2	3	8	-13	-1	18	1	-5

Lineage Cell Therapeutics Inc Annual Cash Flow

All numbers in Millions USD

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Net Income	18	-23	-46	-11	-20	-43	-26	-21	-18
Operating Cash Flow	-42	-30	-30	-31	-19	-23	1	-28	-23
Investing Cash Flow	-10	-10	11	16	13	9	-46	46	-2
Financing Cash Flow	32	55	5	0	29	36	1	6	35
Change in Cash	-20	14	-13	-14	23	23	-44	24	10

Insights on Lineage Cell Therapeutics Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 2 quarters, 1.50M → 2.76M (in $), with an average increase of 45.7% per quarter
POSITIVE IMPACT
Price Rise
In the last 7 days, LCTX stock has moved up by 7.8%
NO EFFECT
Against Peers
In the last 1 year, Beone Medicines Ltd has given 68.4% return, outperforming this stock by 10.4%
NO EFFECT
Against Peers
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 111.5% return, outperforming this stock by 103.7%
NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 4 quarters, -3.03M → -30.46M (in $), with an average decrease of 223.5% per quarter

About Lineage Cell Therapeutics Inc

biotime, inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies developed from what we believe to be the world's premier collection of pluripotent cell assets. the foundation of our core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. pluripotent cells have potential application in many areas of medicine with large unmet patient needs, including various age-related degenerative diseases and degenerative conditions for which there presently are no cures. unlike pharmaceuticals that require a molecular target, therapeutic strategies based on the use of pluripotent cells are generally aimed at regenerating or replacing affected cells and tissues, and therefore may have broader applicability than pharmaceutical products.

Organisation	Lineage Cell Therapeutics Inc
Headquarters	2173 Salk Avenue, Carlsbad, CA, United States, 92008
Industry	Health Technology
CEO	Mr. Brian M. Culley M.A., M.B.A.
E-voting on shares	Click here to vote

Key Management of Lineage Cell Therapeutics Inc

Name	Title
Ms. Brandi L. Roberts CPA, M.B.A.	Consultant
Mr. Brian M. Culley M.A., M.B.A.	CEO, President & Director
Ms. Jill Ann Howe	CFO & Principal Financial and Accounting Officer
Dr. Charlotte Hubbert Ph.D.	Vice President of Corporate Development
Dr. Rami Skaliter Ph.D.	Chief Executive Officer of Cell Cure Neurosciences
Ms. Alexandra Hernandez	Senior Director of Finance & Controller
Dr. Harold D. Waitz	Vice President of Regulatory Affairs & Quality Control
Mr. George A. Samuel III, J.D.	General Counsel & Company Secretary
Ms. Ioana C. Hone	Director of Investor Relations

FAQs

What is Lineage Cell Therapeutics Inc share price today?

Lineage Cell Therapeutics Inc share price today is $1.54 as on September 18, 2025 at 10:41 pm IST. Lineage Cell Therapeutics Inc share today touched a day high of $1.55 and a low of $1.4.

What is the 52 week high and 52 week low for Lineage Cell Therapeutics Inc share?

Lineage Cell Therapeutics Inc share touched a 52 week high of $1.42 on September 17, 2025 and a 52 week low of $0.37 on April 9, 2025. Lineage Cell Therapeutics Inc stock price today i.e. September 18, 2025 at 10:41 pm IST is trending at $1.54,which is -8.45% down from its 52 week high and 321.80% up from its 52 week low.

What is Lineage Cell Therapeutics Inc's market capitalisation today?

Lineage Cell Therapeutics Inc market capitalisation is $0.00T as on September 18, 2025 at 10:41 pm IST.

How to invest in Lineage Cell Therapeutics Inc Stock (LCTX) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Lineage Cell Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Lineage Cell Therapeutics Inc Shares that will get you 0.9740 shares as per Lineage Cell Therapeutics Inc share price of $1.54 per share as on September 18, 2025 at 10:41 pm IST.

What is the minimum amount required to buy Lineage Cell Therapeutics Inc Stock (LCTX) from India?

Indian investors can start investing in Lineage Cell Therapeutics Inc (LCTX) shares with as little as ₹88.114 or $1 (as of September 18, 2025 at 10:41 pm IST) using the INDmoney app.
For example: If you want to invest $10 or ₹881.14 in Lineage Cell Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on September 18, 2025 at 10:41 pm IST). Based on Lineage Cell Therapeutics Inc share’s latest price of $1.54 as on September 18, 2025 at 10:41 pm IST, you will get 6.4935 shares of Lineage Cell Therapeutics Inc. Learn more about fractional shares .

What are the returns that Lineage Cell Therapeutics Inc has given to Indian investors in the last 5 years?

Lineage Cell Therapeutics Inc stock has given 41.84% share price returns and 20.01% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?